| Scorecard |
|---|
|
2 / 5 Stars
|
|
Lipper
2
2
5
3
3
|
|
Zacks Investment Research
2
(Buy)
|
|
Standard & Poor's
4 / 5 Stars
|
|
TheStreet.com
A+
(Buy)
|
Fund Holdings
Asset Allocation
| % Long | % Net | |
|---|---|---|
| Cash | 2.87 | 2.87 |
| Stocks | 86.92 | 86.92 |
| Bonds | 0.0 | 0.0 |
| Other | 0.0 | 0.0 |
| Foreign Bonds | 0.0 | 0.0 |
| Foreign Stocks | 10.21 | 10.21 |
| Convertible | 0.0 | 0.0 |
| Preferred | 0.0 | 0.0 |
Updated 02.28.2013
Top 10 Holdings
Performance as of 04.30.2013
Portfolio as of 02.28.2013
| Ticker | YTD Return % | % Net Assets | |
|---|---|---|---|
| Amgen Inc | AMGN | 21.82 | 6.16 |
| Actavis Inc | ACT | 21.38 | 5.66 |
| Gilead Sciences Inc | GILD | 36.53 | 5.34 |
| Perrigo Company | PRGO | 14.02 | 5.08 |
| Cerner Corporation | CERN | 23.43 | 4.21 |
| Biogen Idec Inc | BIIB | 46.43 | 4.09 |
| Pfizer Inc | PFE | 16.19 | 3.83 |
| Alexion Pharmaceuticals, Inc. | ALXN | 3.13 | 3.68 |
| Novo Nordisk A/S ADR | NVO | 6.86 | 3.49 |
| Johnson & Johnson | JNJ | 21.03 | 3.44 |
